Atrium Health Levine Cancer | Strategic Alliance Partners

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses data from the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

Edward S. Kim, MD, discusses clinical trial eligibility criteria in lung cancer.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Nivolumab monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer.

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Jubilee Brown, MD, discusses the importance of molecular testing immediately after an ovarian cancer diagnosis and how molecular testing will shape the field of ovarian cancer.

R. Wendel Naumann, MD, discusses the criteria for primary debulking versus neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Claud M. Grigg Jr, MD, medical oncologist, Levine Cancer Institute-Ballantyne, Atrium Health, discusses sequencing challenges in renal cell carcinoma (RCC).

Derek R. McHaffie, MD, discusses the role of radiation therapy in the treatment of gastrointestinal cancers and the impact of radionuclide therapy in patients with neuroendocrine tumors.

J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.

Kunal C. Kadakia, MD, highlight key takeaways from the the PROMID, CLARINET, and NETTER-1 trials and explains how their findings have been applied to clinical practice.

Jimmy J. Hwang, MD, sheds light on updates in both metastatic pancreatic cancer and advanced hepatocellular carcinoma that have created new complexities for researchers.

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).